Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

• मुख्य लेखकों: Bruno Fautrel (लेखक), Yoram Bouhnik (लेखक), Carine Salliot (लेखक), Franck Carbonnel (लेखक), Mathurin Fumery (लेखक), Christophe Bernardeau (लेखक), Yves Maugars (लेखक), Mathurin Flamant (लेखक), Fabienne Coury (लेखक), Ben Braithwaite (लेखक), Salima Hateb (लेखक), Janet Addison (लेखक), the PERFUSE investigators (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Background There is a need for published data on real-world use of SB5, an adalimumab (ADL) biosimilar approved in Europe in 2017, on the basis of evidence from pre-clinical and analytic data as well as phase I and III clinical studies demonstrating equivalent efficacy and comparable pharma...